First Line Expansion Public data on brenetafusp in melanoma indicate potential use as a first-line therapy for select patients, expanding the addressable market beyond current lines. This creates opportunities to target leading melanoma centers, support early payer engagement, and establish patient access programs aligned with KIMMTRAK and other TCR therapies.

Combo Therapy Potential Brenetafusp shows activity as monotherapy and in combination with pembrolizumab, suggesting a path for co-development and co-promotion with other immuno-oncology agents. This opens partnerships with oncology centers and payers to support broader adoption in combination regimens.

Pipeline Credibility Ongoing development and positive data support continued growth in Immunocore's pipeline, enabling business development teams to position the company as a growing TCR platform with near-term commercial catalysts and multiple collaboration opportunities.

Financial Backing A strong liquidity position and rising net sales provide resources to scale commercialization, invest in market access, and pursue regional partnerships or licensing deals that broaden the customer base.

Global Payor Readiness KIMMTRAK's demonstrated performance in a diverse patient population helps build payer confidence, supporting proactive reimbursement planning and rapid adoption across Europe and other regions through strategic pricing and access programs.